Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02082431
Other study ID # PDX-001-13
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 2014
Est. completion date July 20, 2020

Study information

Verified date October 2020
Source Mednax Center for Research, Education, Quality and Safety
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine the true incidence of long QT (LQT) amongst a large cohort of subjects diagnosed with unilateral (right/left) or bilateral sensorineural hearing loss.


Description:

The purpose of this study is to determine the true incidence of long QT (LQT) amongst a large cohort of subjects diagnosed with unilateral (right/left) or bilateral sensorineural hearing loss.

The goal of this study is to answer the following questions:

1. What is the incidence of an abnormal ECG (QTc > 450 msec) in neonates greater than a week of age with either unilateral or bilateral Sensorineural hearing loss?

2. What percentage of neonates greater than one week of age with either bilateral or unilateral sensorineural hearing loss and an abnormal ECG have an identifiable genetic mutation?

3. What is the incidence of an abnormal genetic mutation consistent with long QT regardless of the ECG in neonates with bilateral sensorineural hearing loss?


Recruitment information / eligibility

Status Completed
Enrollment 600
Est. completion date July 20, 2020
Est. primary completion date February 18, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 90 Days
Eligibility Inclusion Criteria:

- All newborns who demonstrate a refer in one or both ears on a routine newborn hearing screen

- Documentation of informed consent

- Inborn

- Ability to perform an ABR (auditory brainstem response screen technology) screening test

- No major anomalies

- Subjects' parents willing to provide follow-up data on their child

Exclusion Criteria:

- Newborns with a syndromic cause of hearing loss

- Parents unwilling to provide follow-up data

- Major congenital anomalies

- Major medical problem or conditions. (i.e., hypoxic ischemic encephalopathy (HIE), persistent pulmonary hypertension neonate (PPHN), meconium aspiration, etc.)

- Congenital cytomegalovirus (CMV)

Study Design


Locations

Country Name City State
United States Alexandria Hospital- Inova Health System Alexandria Virginia
United States Jack Jacob Anchorage Alaska
United States Child Cardiology Associates Austin Texas
United States Dell Children's Medical Center Austin Texas
United States Pediatrix Audiology Services Fairfax Virginia
United States Hearts for Hearing Oklahoma City Oklahoma
United States Banner Good Samaritan Hospital Phoenix Arizona
United States St. Joseph's Hospital & Medical Center Phoenix Arizona
United States Swedish American Hospital Rockford Illinois
United States Children's Hospital of San Antonio San Antonio Texas
United States Christus Santa Rosa Westover Hills San Antonio Texas
United States Lawrence and Memorial Hospital Waterford Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Mednax Center for Research, Education, Quality and Safety

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of an abnormal ECG (QTc > 450) in neonates greater than a week of age with either unilateral or bilateral sensorineural hearing loss ECG results to determine QTc length 6 months
Secondary In neonates > 1 week of age with either bilateral or unilateral sensorineural hearing loss and an abnormal ECG, percentage have an identifiable genetic mutation Audiology diagnostic results One year
See also
  Status Clinical Trial Phase
Completed NCT00023036 - Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Completed NCT03746613 - Clinal Evaluation of Navigation Based Functional Ear Surgery Using Image Guided and Robotically Assisted Techniques N/A
Recruiting NCT05568329 - Appreciation for Music Processed by Hearing Aids N/A
Withdrawn NCT05061758 - A Trial of LY3056480 in Patients With SNLH Phase 2
Completed NCT01434446 - The Effect of Sound Stimulation on Hearing Ability N/A
Completed NCT03212924 - Listening Effort in Cochlear Implant Users N/A
Recruiting NCT06053190 - Effects of Clear Speech on Listening Effort and Memory in Sentence Processing N/A
Completed NCT03718975 - Quality Control of CE-Certified Phonak Hearing Aids - 2018_28 N/A
Completed NCT06025097 - Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus. Early Phase 1
Recruiting NCT04102215 - The Efficacy of a Minimally Invasive Direct Cochlear Access Via the HEARO Procedure N/A
Recruiting NCT04108598 - The SeaSHeL National Prospective Cohort Study
Active, not recruiting NCT04750642 - Cochlear Implant With Dexamethasone Eluting Electrode Array N/A
Completed NCT04120116 - FX-322 in Adults With Stable Sensorineural Hearing Loss Phase 2
Recruiting NCT06223724 - Status Telemetry for Cochlear Implantations
Completed NCT02005822 - Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Phase 3
Suspended NCT02616172 - Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss Phase 1/Phase 2
Completed NCT02259595 - Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC Phase 1
Unknown status NCT01902914 - Effectiveness of P02 Digital Hearing Aids Phase 1/Phase 2
Completed NCT00589511 - Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study N/A
Completed NCT03288753 - Comparison Between Neuro 1 and Neuro 2 Cochlear Implant Speech Processors N/A